Literature DB >> 19928920

Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).

Brian D Palmer1, Andrew M Thompson, Hamish S Sutherland, Adrian Blaser, Iveta Kmentova, Scott G Franzblau, Baojie Wan, Yuehong Wang, Zhenkun Ma, William A Denny.   

Abstract

A series of biphenyl analogues of the new tuberculosis drug PA-824 was prepared, primarily by coupling the known (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-ol with iodobenzyl halides, followed by Suzuki coupling of these iodides with appropriate arylboronic acids or by assembly of the complete biaryl side chain prior to coupling with the above alcohol. Antitubercular activity was determined under both replicating (MABA) and nonreplicating (LORA) conditions. para-Linked biaryls were the most active, followed by meta-linked and then ortho-linked analogues. A more detailed study of a larger group of para-linked analogues showed a significant correlation between potency (MABA) and both lipophilicity (CLOGP) and the electron-withdrawing properties of terminal ring substituents ( summation operatorsigma). Selected compounds were evaluated for their efficacy in a mouse model of acute Mycobacterium tuberculosis infection. In vivo activity correlated well with the stability of compounds to microsomal metabolism. Three compounds bearing combinations of lipophilic, electron-withdrawing groups achieved >200-fold higher efficacies than the parent drug.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19928920     DOI: 10.1021/jm901207n

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  28 in total

1.  Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids.

Authors:  David F Bruhn; Michael S Scherman; Aman P Singh; Lei Yang; Jiuyu Liu; Anne J Lenaerts; Richard E Lee
Journal:  Bioorg Med Chem Lett       Date:  2015-12-07       Impact factor: 2.823

2.  Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Authors:  Joseph Cherian; Inhee Choi; Amit Nayyar; Ujjini H Manjunatha; Tathagata Mukherjee; Yong Sok Lee; Helena I Boshoff; Ramandeep Singh; Young Hwan Ha; Michael Goodwin; Suresh B Lakshminarayana; Pornwaratt Niyomrattanakit; Jan Jiricek; Sindhu Ravindran; Thomas Dick; Thomas H Keller; Veronique Dartois; Clifton E Barry
Journal:  J Med Chem       Date:  2011-07-26       Impact factor: 7.446

3.  Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents.

Authors:  Kushalava Reddy Yempalla; Gurunadham Munagala; Samsher Singh; Gurleen Kour; Shweta Sharma; Reena Chib; Sunil Kumar; Priya Wazir; G D Singh; Sushil Raina; Sonali S Bharate; Inshad Ali Khan; Ram A Vishwakarma; Parvinder Pal Singh
Journal:  ACS Med Chem Lett       Date:  2015-09-11       Impact factor: 4.345

4.  Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives.

Authors:  Matshawandile Tukulula; Rajni-Kant Sharma; Maïa Meurillon; Aman Mahajan; Krupa Naran; Digby Warner; Jianxing Huang; Belew Mekonnen; Kelly Chibale
Journal:  ACS Med Chem Lett       Date:  2012-11-26       Impact factor: 4.345

5.  Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis.

Authors:  Rokeya Tasneen; Kathy Williams; Opokua Amoabeng; Austin Minkowski; Khisimuzi E Mdluli; Anna M Upton; Eric L Nuermberger
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

Review 6.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

7.  Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.

Authors:  Meera Gurumurthy; Tathagata Mukherjee; Cynthia S Dowd; Ramandeep Singh; Pornwaratt Niyomrattanakit; Jo Ann Tay; Amit Nayyar; Yong Sok Lee; Joseph Cherian; Helena I Boshoff; Thomas Dick; Clifton E Barry; Ujjini H Manjunatha
Journal:  FEBS J       Date:  2011-11-14       Impact factor: 5.542

8.  Antitubercular and Antiparasitic 2-Nitroimidazopyrazinones with Improved Potency and Solubility.

Authors:  Chee Wei Ang; Lendl Tan; Melissa L Sykes; Neda AbuGharbiyeh; Anjan Debnath; Janet C Reid; Nicholas P West; Vicky M Avery; Matthew A Cooper; Mark A T Blaskovich
Journal:  J Med Chem       Date:  2020-11-05       Impact factor: 7.446

9.  Predicting Mouse Liver Microsomal Stability with "Pruned" Machine Learning Models and Public Data.

Authors:  Alexander L Perryman; Thomas P Stratton; Sean Ekins; Joel S Freundlich
Journal:  Pharm Res       Date:  2015-09-28       Impact factor: 4.200

10.  Highly Potent and Selective N-Aryl Oxamic Acid-Based Inhibitors for Mycobacterium tuberculosis Protein Tyrosine Phosphatase B.

Authors:  Kasi Viswanatharaju Ruddraraju; Devesh Aggarwal; Congwei Niu; Erica Anne Baker; Ruo-Yu Zhang; Li Wu; Zhong-Yin Zhang
Journal:  J Med Chem       Date:  2020-08-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.